Well-designed prospective clinical trials on transcriptome, genome and biochemical analysis on organoids for correct stratification of PLC subtypes could result in organoids profiling becoming a mainstay in both preclinical drug discovery and personalized guidance on future treatment of cancer patients. The gene discussed is HSPG2; the disease is cancer.